L-DABA hydrobromide

Research use only, not for human use.

L-DABA hydrobromide (L-2,4-Diaminobutyric acid hydrobromide) is a potent GABA transaminase inhibitor with antitumor and anticonvulsant activity for the study of neurological disorders.

L-DABA (L-2,4-Diaminobutyric acid) hydrobromide is a week GABA transaminase inhibitor with an IC50 of larger than 500 μM; exhibits antitumor activity in vivo and in vitro.

The tumor cells are irreversibly and totally damaged by incubation with 10 mM L-2,4-Diaminobutyric acid for 24 h at 37°C. The cell-destructive effect by L-DABA hydrobromide is probably due to an osmotic lysis induced by the non-saturated intracellular accumulation of L-DABA hydrobromide. The harmful effect of L-DABA hydrobromide could be abolished by concomitant incubation with L-alanine and L-methionine. Kinetic studies indicates that L-DABA hydrobromide is a non-linear, non-competitive inhibitor of GABA transaminase activity. The L-DABA hydrobromide-induced elevation of GABA levels parallels the inhibition of GABA transaminase activity. L-2,4-Diaminobutyric acid, an amino acid analogue, produceS a cytolytic effect with a human glioma cell line, SKMG-1, and normal human fibroblasts. The concentrations of L-DABA hydrobromide necessary to reduce the cell count to 50% of control following a 24-h incubation at 37°C are 12.5 mM for the human fibroblasts and 20 mM for the glioma cell line.

Treatment with L-DABA hydrobromide results in 43.4% reduction of tumor growth. L-DABA hydrobromide is a more effective inhibitor of GABA transaminase in vivo than in vitro.

——

Others

Other Targets

GABA Receptor | Endogenous Metabolite

——

——

73143-97-2

199.05

C4H11BrN2O2

>98% (HPLC)

——

Br.NCC[C@H](N)C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years